InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.17
(
-0.25%
)
US TECH 100
19,266.00
(
-0.73%
)
Dow Jones
39,134.76
(
0.77%
)
Brent Oil
85.01
(
0.37%
)
Bitcoin
65,001.73
(
0.05%
)
Post# of 1367
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: genisi post# 942

Thursday, 02/17/2011 10:36:42 AM

Thursday, February 17, 2011 10:36:42 AM

Post# of 1367
Kamada is going to start a phase I/II safety and preliminary efficacy clinical trial of its IV Alpha-1 Antitrypsin (AAT) in type 1 diabetes. A couple of more recent basic research works in the area:

http://www.ncbi.nlm.nih.gov/pubmed/21099312

http://www.ncbi.nlm.nih.gov/pubmed/20692406

Baxter's Aralast is being tested by the NIAID for that indication: (looks like the trial is still in its first part (safety))

http://clinicaltrials.gov/ct2/show/NCT01183468

There is one commercial company trying to pursue the area:

http://www.omnibiopharma.com/development
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up